Archives of Physical Medicine and Rehabilitation
Volume 87, Issue 6 , Pages 786-792 , June 2006

Pooled Analysis of the Safety of Botulinum Toxin Type A in the Treatment of Poststroke Spasticity

Presented in part to the American Academy of Physical Medicine and Rehabilitation, October 2004, Phoenix, AZ, and the Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, June 2005, Denver, CO.

  • Catherine C. Turkel, PharmD, MBA

      Affiliations

    • Allergan Inc, Irvine, CA
    • Corresponding Author InformationReprint requests to Catherine C. Turkel, PharmD, MBA, Clinical Development, Allergan Inc, 2525 Dupont Dr, Irvine, CA 92612
    • ,
  • Beta Bowen, MS

      Affiliations

    • Allergan Inc, Irvine, CA
    • ,
  • Jingyu Liu, PhD

      Affiliations

    • Allergan Inc, Irvine, CA
    • ,
  • Mitchell F. Brin, MD

      Affiliations

    • Allergan Inc, Irvine, CA
    • University of California, Irvine, CA

References 

  1. Centers for Disease Control and Prevention. National Center for Health Statistics. Stroke fact sheet. Available at: http://www.cdc.gov/cvh/library/fs_stroke.htm. Accessed June 21, 2005.
  2. Wade D . Stroke (acute cerebrovascular disease) . In:  Stevens A ,  Raftery J editor. Health care needs assessments . Oxford: Radcliffe Medical Pr; 1994;p. 111–255
  3. Mayer NH , Esquenazi A , Childers MK . Common patterns of clinical motor dysfunction . Muscle Nerve . 1997;20(Suppl 6):S21–S35
  4. Viitanen M , Fugl-Meyer KS , Bernspang B , Fugl-Meyer AR . Life satisfaction in long-term survivors after stroke . Scand J Rehabil Med . 1988;20:17–24
  5. Åström M , Asplund K , Astrom T . Psychosocial function and life satisfaction after stroke . Stroke . 1992;23:527–531
  6. Jonkman EJ , de Weerd AW , Vrijens NL . Quality of life after a first ischemic stroke. Long-term developments and correlations with changes in neurological deficit, mood and cognitive impairment . Acta Neurol Scand . 1998;98:169–175
  7. Duncan PW , Samsa GP , Weinberger M , et al.   Health status of individuals with mild stroke . Stroke . 1997;28:740–745
  8. Turkel C , Sissins P . Functional activities affected by poststroke spasticity . [abstract] Arch Phys Med Rehabil . 2004;85:E52
  9. O’Brien CF , Seeberger LC , Smith DB . Spasticity after stroke. Epidemiology and optimal treatment . Drugs Aging . 1996;9:332–340
  10. Brin MF . Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity . Muscle Nerve . 1997;20(Suppl 6):S208–S220
  11. Wissel J , Muller J , Dressnandt J , et al.   Management of spasticity associated pain with botulinum toxin A . J Pain Symptom Manage . 2000;20:44–49
  12. Farmer SE , James M . Contractures in orthopaedic and neurological conditions (a review of causes and treatment) . Disabil Rehabil . 2001;23:549–558
  13. Brashear A . Use of botulinum toxin type A in poststroke spasticity . Expert Rev Neurotherapeutics . 2003;3:271–277
  14. Das TK , Park DM . Botulinum toxin in treating spasticity . Br J Clin Pract . 1989;43:401–403
  15. Hesse S , Lucke D , Malezic M , et al.   Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients . J Neurol Neurosurg Psychiatry . 1994;57:1321–1324
  16. Reiter F , Danni M , Lagalla G , Ceravolo G , Provinciali L . Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke . Arch Phys Med Rehabil . 1998;49:532–535
  17. Kirazli Y , On AY , Kismali B , Aksit R . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke . Am J Phys Med Rehabil . 1998;77:510–515
  18. Lagalla G , Danni M , Reiter F , Ceravolo M , Provinciali L . Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb . Am J Phys Med Rehabil . 2000;79:377–384
  19. Esquenazi A , Mayer N . Botulinum toxin for the management of muscle overactivity and spasticity after stroke . Curr Atheroscler Rep . 2001;3:295–298
  20. Brashear A , Gordon MF , Elovic E , et al.   Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke . N Engl J Med . 2002;347:395–400
  21. Childers MK , Brashear A , Jozefczyk P , et al.   Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke . Arch Phys Med Rehabil . 2004;85:1063–1069
  22. Gordon MF , Brashear A , Elovic E , et al.   Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke . Neurology . 2004;63:1971–1973
  23. Turner-Stokes L , Ward A . Botulinum toxin in the management of spasticity in adults . Clin Med . 2002;2:128–130
  24. Richardson D , Sheean G , Werring D , et al.   Evaluating the role of botulinum toxin in the management of focal hypertonia in adults . J Neurol Neurosurg Psychiatry . 2000;69:499–506
  25. Bhakta BB . Management of spasticity in stroke . Br Med Bull . 2000;46:476–485
  26. Barnes MP . Spasticity (a rehabilitation challenge in the elderly) . Gerontology . 2001;47:295–299
  27. Simpson DM , Alexander DN , O’Brien CF , et al.   Botulinum toxin type A in the treatment of upper extremity spasticity (a randomized, double-blind, placebo-controlled trial) . Neurology . 1996;46:1306–1310
  28. Beyth RJ , Shorr RI . Epidemiology of adverse drug reactions in the elderly by drug class . Drugs Aging . 1999;14:231–239
  29. Walker AE , Robins M , Weinfeld FD . Clinical findings . Stroke . 1981;12:I13–I31
  30. Black-Schaffer RM , Kirsteins AE , Harvey RL . Stroke rehabilitation. 2. Co-morbidities and complications . Arch Phys Med Rehabil . 1999;80(5 Suppl 1):S8–S16
  31. Ashworth B . Preliminary trial of carisprodol in multiple sclerosis . Practitioner . 1964;192:540–542
  32. Bohannon RW , Smith MB . Interrater reliability of a modified Ashworth scale of muscle spasticity . Phys Ther . 1987;67:206–207
  33. Allergan Inc . Evaluation of muscle tone in poststroke patients using two scoring systems . Irvine: Allergan; 1998; Internal study report 191622-007.
  34. Allergan Inc . BOTOX prescribing information . Irvine: Allergan Inc; 2005;
  35. Evers SM , Driessen GA , Ament AJ . The use of mental health care facilities after stroke. A cost analysis . Int J Technol Assess Health Care . 2002;18:33–45
  36. Lindblad U , Rastam L , Ranstam J . Stroke morbidity in patients treated for hypertension—The Skaraborg Hypertension Project . J Intern Med . 1993;233:155–163
  37. Marinkovic S , Badlani G . Voiding and sexual dysfunction after cerebrovascular accidents . J Urol . 2001;165:359–370
  38. Tuhrim S . Stroke risk factors . CNS Spectrums . 2000;5:70–74
  39. Van Heugten CM , Dekker J , Deelman GB , Stehmann-Saris JC , Kinebanian A . Rehabilitation of stroke patients with apraxia (the role of additional cognitive and motor impairments) . Disabil Rehabil . 2000;22:547–554
  40. Silverman IE , Restrepo L , Mathews GC . Poststroke seizures . Arch Neurol . 2002;59:195–201
  41. Bladin CF , Alexandrov AV , Bellavance A , et al.   Seizures after stroke (a prospective multicenter study) . Arch Neurol . 2000;57:1617–1622
  42. Jankovic J , Brin MF . Botulinum toxin (historical perspective and potential new indications) . Muscle Nerve . 1997;20(Suppl 6):S129–S145
  43. Ghosh B , Das SK . Botulinum toxin (a dreaded toxin for use in human being) . J Indian Med Assoc . 2002;100:607–614
  44. Dutton JJ . Botulinum-A toxin in the treatment of craniocervical muscle spasms (short- and long-term, local and systemic effects) . Surv Ophthalmol . 1996;41:51–65
  45. Naumann M , Lowe NJ . Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis (randomised, parallel group, double blind, placebo controlled trial) . BMJ . 2001;323:596–599
  46. Carruthers JA , Lowe NJ , Menter MA , et al.   A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines . J Am Acad Dermatol . 2002;46:840–849
  47. Gracies JM , Nance P , Elovic E , McGuire J , Simpson DM . Traditional pharmacological treatments for spasticity. Part II: general and regional treatments . Muscle Nerve . 1997;20(Suppl 6):S92–S120
  48. Kita M , Goodkin DE . Drugs used to treat spasticity . Drugs . 2000;59:487–495
  49. Meythaler JM , Guin-Renfroe S , Johnson A , Brunner RM . Prospective assessment of tizanidine for spasticity due to acquired brain injury . Arch Phys Med Rehabil . 2001;82:1155–1163
  50. Hulme A , MacLennan WJ , Ritchie RT , John VA , Shotton PA . Baclofen in the elderly stroke patient (its side-effects and pharmacokinetics) . Eur J Clin Pharmacol . 1985;29:467–469
  51. Brin M , Aoki KR , Dressler D . Pharmacology of botulinum toxin therapy . In:  Brin MF ,  Comella C ,  Jankovic J editor. Dystonia (etiology, clinical features, and treatment) . Philadelphia: Lippincott, Williams & Wilkins; 2004;p. 93–112
  52. Aoki RA . Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety . Toxicon . 2002;40:923–928
  53. Aoki KR . A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice . Toxicon . 2001;39:1815–1820
  54. Brashear A , McAfee AL , Kuhn ER , Ambrosius WT . Treatment with botulinum toxin type B for upper-limb spasticity . Arch Phys Med Rehabil . 2003;84:103–107
  55. Gormley ME , O’Brien CE , Yablon SA . A clinical overview of treatment decisions in the management of spasticity . Muscle Nerve . 1997;20(Suppl 6):S14–S20
  56. Defazio G , Abbruzzese G , Girlanda P , et al.   Botulinum toxin A treatment for primary hemifacial spasm (a 10-year multicenter study) . Arch Neurol . 2002;59:418–420
  57. Hsiung GY , Das SK , Ranawaya R , Lafontaine AL , Suchowersky O . Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period . Mov Disord . 2002;17:1288–1293
  58. Naumann M , Jankovic J . Safety of botulinum toxin type A (a systematic review and meta-analysis) . Curr Med Res Opin . 2004;20:981–990
  59. Turkel C , Bowen B , Liu J , Brin M . A pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity . [abstract] Arch Phys Med Rehabil . 2004;85:E8
  60. Allergan Inc . A multicenter study evaluating the utility of clinical scales for measuring functional changes in patients with focal, upper-limb spasticity poststroke . Irvine: Allergan; 2003; Internal study report 191622-044.
  61. Turkel C , Dru R , Liu J . Double-blind, randomized, dose-ranging study of BOTOX (botulinum toxin type A) purified neurotoxin complex for treating focal spasticity poststroke . [abstract] Naunyn Schmiedebergs Arch Pharmacol . 2002;365(Suppl 2):R47; ABS-155
  62. de Beyl DZ , Csiba L , Yakovleff A , et al.   A multicenter, double-blind, placebo-controlled trial to evaluate dosing, safety, and efficacy of intramuscular botulinum toxin type A for the management of upper limb spasticity post-stroke . [abstract] Eur J Neurol . 2000;7(Suppl 3):23; ABS SC-44
  63. Allergan Inc . A two part multicentre study of BOTOX (botulinum toxin type A) in the treatment of lower-limb spasticity during stroke rehabilitation (part I–double-blind, placebo-controlled, parallel, randomised & part II–open label follow up) . Irvine: Allergan; 2002; Internal study report BTOX-702-8051.
  64. Allergan Inc . A randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, efficacy and dosing of BOTOX (botulinum toxin type A) purified neurotoxin complex for the treatment of lower limb spasticity in post-stroke patients . Irvine: Allergan; 2001; Internal study report BTOX-138/139-8051.
  65. Allergan Inc . A multicenter, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, dosing and efficacy of a single dose of BOTOX (botulinum toxin type A) purified neurotoxin complex for the management of lower limb spasticity after stroke . Irvine: Allergan; 2001; Internal study report 191622-501.

 Supported by Allergan Inc.A commercial party having a direct financial interest in the results of the research supporting this article has conferred or will confer a financial benefit upon the authors. Turkel, Bowen, Liu, and Brin are employees of Allergan, which manufactures the drug used in this study, and all own Allergan stock and/or stock options.

PII: S0003-9993(06)00162-6

doi: 10.1016/j.apmr.2006.02.015

Archives of Physical Medicine and Rehabilitation
Volume 87, Issue 6 , Pages 786-792 , June 2006

Article Tools